Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies. This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies. The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is currently progressing in an ongoing Phase I/II DOMISOL trial for the treatment of solid tumours. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!